Mechanistic insights into lactate-driven pathogenesis in diabetic kidney disease
4 affiliations
- 1Beijing Luhe Hospital, Capital Medical University
- 2Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University
- 3Beijing Key Laboratory of Artificial Intelligence and Cell-based Medical Engineering for Interdisciplinary Innovation and Clinical Translation
- 4Laboratory for Clinical Medicine, Capital Medical University
Abstract
Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease worldwide, yet current therapeutic approaches fail to fully halt its progression. Emerging evidence identifies lactate not merely as a glycolytic byproduct, but as a critical signaling molecule that drives DKD pathogenesis via lysine lactylation. This review delineates the mechanistic cascade from upstream metabolic dysregulation to epigenetic reprogramming and renal injury. We first describe how the hyperglycemic and hypoxic microenvironment stabilizes hypoxia-inducible factor-1α (HIF-1α), initiating a positive feedback loop that amplifies glycolytic flux and lactate accumulation. Then, we discuss the dynamic regulation of lactylation by “writer” enzymes and “eraser” enzymes. Furthermore, we analyze how lactate-induced lactylation may contribute to metabolic and immune-inflammatory remodeling across key renal cells: promoting podocyte epithelial-mesenchymal transition (EMT) and autophagy suppression; driving tubular fibrosis and ferroptosis via specific lactylation axes; and activating glomerular endothelial NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasomes. Beyond lactylation, we address other lactate-mediated mechanisms, including GPR81 signaling and intracellular acidification. Finally, we evaluate therapeutic strategies targeting this pathway-such as SGLT2 inhibitors and traditional Chinese medicine-and discuss the challenges in clinical translation. By integrating the latest mechanistic advances, this review discusses lactate-induced lactylation as a potential hub that may connect metabolic, epigenetic, and immune injury, while acknowledging that renal inflammation in DKD arises from diverse upstream pathways, providing a roadmap for the development of next-generation biomarkers and targeted therapies.
Related
- Periostin in diabetic kidney disease: mechanistic insights, biomarkers, and therapeutic perspectives
- Associations between serum lactate and renal dysfunction in diabetic kidney disease: An exploratory analysis integrating animal experiments, clinical cohorts, and bioinformatic approaches
- Mechanistic insights of Artemisia-derived therapeutics in Alzheimer’s disease (AD): from crude botanical extracts to artemisinin and derivatives
- SGLT2 inhibitors and exercise in diabetic kidney disease: mechanistic rationale, emerging clinical evidence, and future perspectives.
- Traditional Chinese Medicine for Diabetic Kidney Disease: Predominantly Preclinical Evidence, Mechanistic Pathways, and Translational Challenges.
BibTeX
@article{he2026mechanistic,
title = {{Mechanistic insights into lactate-driven pathogenesis in diabetic kidney disease}},
author = {Shihao He and Longyan Yang and Ruili Yin},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1950569},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1950569/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mechanistic insights into lactate-driven pathogenesis in diabetic kidney disease
AU - Shihao He
AU - Longyan Yang
AU - Ruili Yin
PY - 2026
DA - 2026/10/22
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1950569
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1950569/full
AB - Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease worldwide, yet current therapeutic approaches fail to fully halt its progression. Emerging evidence identifies lactate not merely as a glycolytic byproduct, but as a critical signaling molecule that drives DKD pathogenesis via lysine lactylation. This review delineates the mechanistic cascade from upstream metabolic dysregulation to epigenetic reprogramming and renal injury. We first describe how the hyperglycemic and hypoxic microenvironment stabilizes hypoxia-inducible factor-1α (HIF-1α), initiating a positive feedback loop that amplifies glycolytic flux and lactate accumulation. Then, we discuss the dynamic regulation of lactylation by “writer” enzymes and “eraser” enzymes. Furthermore, we analyze how lactate-induced lactylation may contribute to metabolic and immune-inflammatory remodeling across key renal cells: promoting podocyte epithelial-mesenchymal transition (EMT) and autophagy suppression; driving tubular fibrosis and ferroptosis via specific lactylation axes; and activating glomerular endothelial NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasomes. Beyond lactylation, we address other lactate-mediated mechanisms, including GPR81 signaling and intracellular acidification. Finally, we evaluate therapeutic strategies targeting this pathway-such as SGLT2 inhibitors and traditional Chinese medicine-and discuss the challenges in clinical translation. By integrating the latest mechanistic advances, this review discusses lactate-induced lactylation as a potential hub that may connect metabolic, epigenetic, and immune injury, while acknowledging that renal inflammation in DKD arises from diverse upstream pathways, providing a roadmap for the development of next-generation biomarkers and targeted therapies.
SN - 1663-9812
ER -